269 results on '"Alazawi, William"'
Search Results
2. Non-invasive Tests of Fibrosis: Does One Size Fit All?
3. Measuring NAFLD models of care
4. National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022
5. A global research priority agenda to advance public health responses to fatty liver disease
6. WED-275 Understanding barriers to adoption of clinical guidelines for metabolic dysfunction-associated steatotic liver disease among hepatologists in Europe
7. THU-236-YI Oxysterol treatment causes indirect stellate cell activation: a potential mechanism linking steroid metabolising enzyme dysregulation with fibrosis
8. WED-248 A four-country modelling study on doubling MASH diagnostic rates by 2027
9. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group
10. Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank
11. The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population
12. Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study
13. Nonalcoholic Fatty Liver Disease
14. Socioeconomic Factors Associated With Liver-Related Mortality From 1985 to 2015 in 36 Developed Countries
15. Authors’ reply to McKenna-Barry and Ryan
16. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke : findings from matched cohort study of 18 million European adults
17. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
18. National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022
19. Improving prevention strategies for cardiometabolic disease
20. A global action agenda for turning the tide on fatty liver disease.
21. Automated and reproducible cell identification in mass cytometry using neural networks
22. Update on Treatment for Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis.
23. Atypical Chemokine receptors regulate the induction of ‘disease-associated’ LSEC by modulating Endothelial-to-Mesenchymal transition (EndMT) during liver fibrosis
24. A social media listening study of patients’ experiences toward NAFLD (LISTEN-NAFLD)
25. The national audit of non-alcoholic fatty liver disease (NAFLD) identifies variations and shortfalls in delivery of care in the UK
26. Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)
27. Low rates of fibrosis scoring in the primary care records of 5987 people living with type 2 diabetes
28. A systematic review and meta-analysis of the prevalence and cross-sectional severity of South Asian patients with non-alcoholic fatty liver disease
29. B-cell activating factor in non-alcoholic steatohepatitis
30. Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review
31. Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol
32. Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
33. Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease
34. Abnormalities of the genome and transcriptome in the progression of cervical neoplasia
35. Renal dysfunction in liver disease
36. A global research priority agenda to advance public health responses to fatty liver disease
37. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
38. Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential?
39. Factors associated with HCC stage at presentation and survival in an ethnically diverse UK population
40. Investigating the function of Endothelial-To-Mesenchymal transition during liver fibrogenesis using a Liver-On-A-Chip platform
41. Pro-inflammatory liver-homing T cells in peripheral blood, liver and adipose tissue in patients with NASH and changes in post-bariatric surgery samples
42. Single-cell phenotypes of peripheral blood im- mune cells in early and late stages of non-alcoholic fatty liver disease.
43. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
44. P94 Factors associated with HCC stage at presentation and survival in an ethnically diverse UK population
45. What’s new in non-alcoholic fatty liver disease?
46. Testing for liver scarring at the diabetes annual review
47. Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis
48. Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity
49. The growing prevalence of nonalcoholic fatty liver disease (NAFLD), determined by fatty liver index, amongst young adults in the United States. A 20-year experience
50. Other liver viruses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.